Literature DB >> 18449174

Hyperphosphatemia of chronic kidney disease.

Keith A Hruska1, Suresh Mathew, Richard Lund, Ping Qiu, Raymond Pratt.   

Abstract

Observational studies have determined hyperphosphatemia to be a cardiovascular risk factor in chronic kidney disease. Mechanistic studies have elucidated that hyperphosphatemia is a direct stimulus to vascular calcification, which is one cause of morbid cardiovascular events contributing to the excess mortality of chronic kidney disease. This review describes the pathobiology of hyperphosphatemia that develops as a consequence of positive phosphate balance in chronic kidney disease and the mechanisms by which hyperphosphatemia acts on neointimal vascular cells that are stimulated to mineralize in chronic kidney disease. The characterization of hyperphosphatemia of chronic kidney disease as a distinct syndrome in clinical medicine with unique disordered skeletal remodeling, heterotopic mineralization and cardiovascular morbidity is presented.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18449174      PMCID： PMC2735026          DOI： 10.1038/ki.2008.130

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  76 in total

1.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.

Authors:  M Coco; H Rush
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

2.  Serum phosphate levels and mortality risk among people with chronic kidney disease.

Authors:  Bryan Kestenbaum; Joshua N Sampson; Kyle D Rudser; Donald J Patterson; Stephen L Seliger; Bessie Young; Donald J Sherrard; Dennis L Andress
Journal:  J Am Soc Nephrol       Date:  2004-12-22       Impact factor: 10.121

3.  Regulation of fibroblast growth factor-23 signaling by klotho.

Authors:  Hiroshi Kurosu; Yasushi Ogawa; Masayoshi Miyoshi; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Michel G Baum; Susan Schiavi; Ming-Chang Hu; Orson W Moe; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2006-01-25       Impact factor: 5.157

4.  Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process.

Authors:  Mohammed S Razzaque; Despina Sitara; Takashi Taguchi; René St-Arnaud; Beate Lanske
Journal:  FASEB J       Date:  2006-01-25       Impact factor: 5.191

5.  Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.

Authors:  Yelena Slinin; Robert N Foley; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2005-04-06       Impact factor: 10.121

Review 6.  Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism.

Authors:  I B Salusky; W G Goodman; B D Kuizon
Journal:  Pediatr Nephrol       Date:  2000-07       Impact factor: 3.714

7.  A novel mechanism for skeletal resistance in uremia.

Authors:  E Slatopolsky; J Finch; P Clay; D Martin; G Sicard; G Singer; P Gao; T Cantor; A Dusso
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

8.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 9.  New insights into mineral and skeletal regulation by active forms of vitamin D.

Authors:  G N Hendy; K A Hruska; S Mathew; D Goltzman
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

10.  Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome.

Authors:  Matthew R Davies; Richard J Lund; Suresh Mathew; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121
View more
  109 in total

Review 1.  The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals.

Authors:  Solmaz Khoshniat; Annabelle Bourgine; Marion Julien; Pierre Weiss; Jérôme Guicheux; Laurent Beck
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

2.  Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients.

Authors:  Wan-Chuan Tsai; Ju-Yeh Yang; Chia-Chin Luan; Yuh-Jiun Wang; Yu-Chuan Lai; Lie-Chuan Liu; Yu-Sen Peng
Journal:  Clin Exp Nephrol       Date:  2015-12-11       Impact factor: 2.801

3.  Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Authors:  Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

4.  Multi-Trajectory Models of Chronic Kidney Disease Progression.

Authors:  Philipp Burckhardt; Daniel S Nagin; Rema Padman
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

Review 5.  Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?

Authors:  Francesco Locatelli; Lucia Del Vecchio
Journal:  J Nephrol       Date:  2017-07-17       Impact factor: 3.902

Review 6.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

7.  Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Authors:  Geoffrey A Block; David P Rosenbaum; Maria Leonsson-Zachrisson; Magnus Åstrand; Susanne Johansson; Mikael Knutsson; Anna Maria Langkilde; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

8.  Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia.

Authors:  Domenick A Prosdocimo; Steven C Wyler; Andrea M Romani; W Charles O'Neill; George R Dubyak
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

9.  Potential Role of H-Ferritin in Mitigating Valvular Mineralization.

Authors:  Katalin Éva Sikura; László Potor; Tamás Szerafin; Abolfazl Zarjou; Anupam Agarwal; Paolo Arosio; Maura Poli; Zoltán Hendrik; Gábor Méhes; Melinda Oros; Niké Posta; Lívia Beke; Ibolya Fürtös; György Balla; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

10.  No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Authors:  Rajnish Mehrotra; Carmen A Peralta; Shu-Cheng Chen; Suying Li; Michael Sachs; Anuja Shah; Keith Norris; Georges Saab; Adam Whaley-Connell; Bryan Kestenbaum; Peter A McCullough
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.